Sorafenib and Bevacizumab Combination Targeted Therapy in Advanced Neuroendocrine Tumor: A Phase II Study of the Spanish Neuroendocrine Tumor Group (GETNE0801) Abstract #280

Introduction: Sorafenib (S) and bevacizumab (B) as single agents have shown efficacy and acceptable toxicity in NETs phase II trials. S+B combination has shown manageable toxicity in phase I trials in solid tumors.
Aim(s): To evaluate the efficacy and toxicity of the combination of S and B in this setting.
Materials and methods: Phase II trial. Eligibility criteria: measurable, non-resectable, histologically confirmed moderately or well-differentiated NETs; one prior chemotherapy allowed; ECOG-PS 0-2. Pts were treated during six months and followed up additional six months. Treatment: S 200mg bid (days one to five of each week) and B 5mg/Kg once every two weeks (day one, week one).
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Mrs. Cristina Garrido

To read results and conclusion, please login ...

Further abstracts you may be interested in

#557 The Role of Chemotherapy in the Management of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): The Large Experience of the Spanish National Tumor Registry (RGETNE)
Introduction: GEPNETs represent a heterogenous family of tumors of challenging clinical management. Treatment of advanced disease is evolving, including some recent relevant achievements with novel targeted agents. How to best integrate these new agents with conventional chemotherapy(CT) is still a matter of debate.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: MD Rocio Garcia-Carbonero
Keywords: chemotherapy
#1094 Experience with Bevacizumab in Neuroendocrine Tumors
Introduction: Bevacizumab has shown promising activity in neuroendocrine tumors (NET) in combination with a multitude of other substances.
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr. med. Leonidas Apostolidis
#1526 Therapeutic Strategies in Patients with Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NEN): Results from the National Neuroendocrine Cancer Registry of Spain (R-GETNE)
Introduction: The Spanish National Neuroendocrine Cancer Registry is a hospital-based registry of GEP-NENs launched by GETNE in 2001.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Others
Presenting Author: PhD Paula Jimenez-Fonseca
#2265 Activity of Bevacizumab in Neuroendocrine Neoplasms
Introduction: The combination of the anti-VEGF antibody bevacizumab (BEV) with a multitude of other antineoplastic substances has shown promising activity in neuroendocrine neoplasms (NEN). However, data proving the superiority of BEV-containing vs. BEV-free protocols are lacking.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment -Targeted therapies
Presenting Author: Dr. med. Leonidas Apostolidis
#2210 213 Bi and Ac 225 DOTATOC Receptor Labeled Targeted Alpha-Radionuclide Therapy in Neuroendocrine Tumors Refractory to Beta Radiation - Early Experience
Introduction: Radiopeptide therapy using a somatostatin analogue labeled with alpha emitters Actinium 225 and Bismuth 213 DOTATOC is a novel therapeutic option in metastatic neuroendocrine tumors (NET), with few alternative therapeutic options for patients with beta refractory disease. We report the first experience with 213Bi and Ac225 DOTATOC targeted alpha therapy (TAT) in treatment of well differentiated metastatic NETs at a tertiary care hospital in India.
Conference: 15th Annual ENETS conference (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Dr Sugandha Dureja
Authors: Dureja S, Sen I, Pant V, Thak P, ...
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.